def Pub():
	PUB_DICT = {"publications": [['05-05-2016', 'Breast Cancer Biomarker that is a potential prognostic factor', '02-09-2016', 'Biomarkers of prognosis', 'Micro RNA Biomarkers can have a treatment strategy.  This study also included 161 samples from Guangzhou', 'Biology, Survival calculations, prognosis', 'http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774458/'], ['05-05-2016', 'Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)', '06-02-2015', 'Obesity and higher BMI is a potential prognostic factor', "Jennifer Ligibel who led this study works at DFCI.  Obesity's link to poor prognosis seems well documented, but this study is recent and points to other links if you decide to pursue this thread", 'Weight', 'http://jnci.oxfordjournals.org/content/107/9/djv179.long'], ['05-11-2016', 'IBIS I, IBIS III studies', '12-11-2014', 'IBIS I study: Risk reduction from Tamoxifen based on large longitudinal study', 'Highlights the risk reduction from a very large longitudinal study of taking Tamoxifen.  It seems evident that ER+ women have the most significant risk reduction.  Dig into this data', 'Hormone therapy', 'http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/abstract'], ['05-15-2016', 'Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State', '02-10-2015', 'Longitudinal analysis of BC incidence and mortality by age, cancer sub-type, race and gender, socioeconomic status across 46 states', 'One key question I\'d like answered is: why are some women successfully treated vs. others.  The variables discussed in this report helps answer a few of the drivers.\n[Not sure if this study successfully linked incidence data to mortality data - "Linking incidence data with mortality to assess survival and population-based mortality by subtype will provide insight into whether the high rates of HR+/HER2- represent overdiagnosis of nonlethal invasive cancers or effective treatment of cancer detected early"]', 'Analysis of Breast Cancer Incidence and Mortality', 'http://jnci.oxfordjournals.org/content/107/6/djv048.full?sid=c56f408a-1b77-425f-b785-9aa68fe02f6c'], ['05-15-2016', 'Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin', '08-14-2014', 'An integrative analysis using five genome-wide platforms and one proteomic platform on 3,527 specimens from 12 cancer types, revealing a unified classification into 11 major subtypes', 'This genomic signature data is publicly available for analysis according to the article.  Read and later analyze this data set. ["Rich resource for data-mining and biological discovery"]', 'Molecular analysis of cancer types', 'http://www.sciencedirect.com/science/article/pii/S0092867414008769'], ['05-15-2016', 'Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S', '11-01-2007', 'Cancer incidence, mortality, and stage distributions among Asians and Pacific Islanders (API) residing in the U.S. and note health disparities, using the cancer experience of the non-Hispanic white population as the referent group', 'One of the ONLY and earliest studies reviewing the disparities and /or comparing incidence and mortality rates from cancer for Asian and pacific Islanders vs. other populations.  Lots of data is now available to do a similar analysis with current data.  DO IT.', 'Indcidence and mortality among Asians', 'http://link.springer.com/article/10.1007%2Fs10552-007-9088-3'], ['05-15-2016', 'Adolescent and Young Adult Cancer Survival', '11-01-2014', 'AYA patients 15–39 years old, diagnosed during 2000–2008 with malignant cancers were selected from the SEER 17 registries data. Selected cancers were analyzed for incidence and five-year relative survival by histology, stage, and receptor subtypes', "This report indicates that the AYA survival rates for young women with certain types of cancers including breast cancer is lower than women in other age brackets.  Three things: a) the info is based on 2000-2008 data that is old, when treatment (including ovarian suppression) was different. b) The hazard ratio calculations are not clear as they've been drawn from SEER*Stat databases, c) The actual prognosis % for 30-40 year old women with ER+ is quite high even though the HR is suggested to be relatively lower than the rest of the population.  Update this analysis using new data and looking more closely at their methods", 'Incidence and mortality among Young Adults', 'http://jncimono.oxfordjournals.org/content/2014/49/228.full'], ['05-16-2016', 'Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base', '11-01-2015', 'Explores racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer. Methods: The National Cancer Database was queried to identify women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. Chemotherapy use and rate of pathologic complete response (pCR) was determined for various racial/ethnic groups', "Research gate is an interesting platform to publish scientific research.  Although a lot of journals don't have direct publications related to racial disparities (recent ones), this platform seems to have a fair amount of interesting analyses.  Scrub through research gate for other similar links when you have time.", 'Racial difference in neoadjuvant chemo', 'https://www.researchgate.net/publication/284545904_Racial_Differences_in_the_Use_and_Outcome_of_Neoadjuvant_Chemotherapy_for_Breast_Cancer_Results_From_the_National_Cancer_Data_Base'], ['05-18-2016', 'Estimating relative survival for cancer patients from the SEER Program using\nexpected rates based on Ederer I versus Ederer II method', '01-01-2011', 'Compares three of the existing survival calculation methods used by the SEET*Stat program of the US Cancer Statistics organization', 'Understand how the five year survival stats have been calculated and use fine grain data to extrapolate the actual survival stats by race and age group', 'Survival calculations, prognosis', 'http://surveillance.cancer.gov/reports/tech2011.01.pdf'], ['05-25-2016', 'Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer', '03-18-2015', 'Compares prognosis of ER+ / PR+ BC with ER+ / PR- and ER- / PR- BC.  Although the title is alarming, the 5 year DFS rates of ER+/PR- is relatively similar to ER+ / PR+ BC, and the 10 year DFS trails off a little but remains above 80%', 'Be cautious of studies that claim "poorer" prognosis for ER+/ PR- cancers because they typically mean relatively poor and also tend to include smaller %s of this subtype.  Understand the biological significance of being PR-', 'Survival calculations, prognosis, ER+, PR-', 'http://www.ncbi.nlm.nih.gov/pubmed/25880075']]}

	return PUB_DICT